1. Home
  2. GDO vs ORMP Comparison

GDO vs ORMP Comparison

Compare GDO & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Global Corporate Defined Opportunity Fund Inc.

GDO

Western Asset Global Corporate Defined Opportunity Fund Inc.

N/A

Current Price

$10.71

Market Cap

86.7M

Sector

Finance

ML Signal

N/A

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

N/A

Current Price

$3.42

Market Cap

141.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GDO
ORMP
Founded
N/A
2002
Country
United States
United States
Employees
N/A
13
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
86.7M
141.3M
IPO Year
2009
2010

Fundamental Metrics

Financial Performance
Metric
GDO
ORMP
Price
$10.71
$3.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
32.0K
155.4K
Earning Date
01-01-0001
03-27-2026
Dividend Yield
N/A
7.16%
EPS Growth
N/A
N/A
EPS
N/A
1.26
Revenue
N/A
$1,340,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.77
Revenue Growth
N/A
N/A
52 Week Low
$10.29
$1.82
52 Week High
$12.15
$3.76

Technical Indicators

Market Signals
Indicator
GDO
ORMP
Relative Strength Index (RSI) 20.22 49.33
Support Level N/A $3.21
Resistance Level $11.71 $3.72
Average True Range (ATR) 0.11 0.17
MACD -0.02 0.00
Stochastic Oscillator 0.00 46.95

Price Performance

Historical Comparison
GDO
ORMP

About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.

Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Share on Social Networks: